Delcath Systems Inc（DCTH）財務資料DCTHDelcath Systems Inc

Delcath Systems Inc (DCTH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is HEPZATO KIT, accounting for 93.2% of total sales, equivalent to $27.16M. Another important revenue stream is CHEMOSAT. Understanding this composition is critical for investors evaluating how DCTH navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Delcath Systems Inc maintains a gross margin of 89.75%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 8.22%, while the net margin is 9.16%. These profitability ratios, combined with a Return on Equity (ROE) of 0.47%, provide a clear picture of how effectively DCTH converts its operational activities into shareholder value.

In the context of the broader market, DCTH competes directly with industry leaders such as ANGO and SSII. With a market capitalization of $510.77M, it holds a significant position in the sector. When comparing efficiency, DCTH's gross margin of 89.75% stands against ANGO's 56.00% and SSII's 48.46%. Such benchmarking helps identify whether Delcath Systems Inc is trading at a premium or discount relative to its financial performance.

Delcath Systems has shown significant revenue growth, with Q2 2026 revenues at $29.1 million, up 20% year-over-year. The gross margin has also improved to 89.75%, reflecting strong operational efficiency. The company has returned to profitability with a net income of $2.67 million in Q2 2026, after two quarters of losses.